Investors

Investors

Since the company’s inception, Tetraphase has developed a robust antibiotics platform based on the tetracycline core chemical structure, which offers the potential to dramatically improve the treatment of serious bacterial infections. Tetraphase has utilized this fully-synthetic chemistry technology to create a pipeline of novel tetracycline antibiotics, particularly those with activity against the toughest multidrug-resistant Gram-negative bacteria.

NASDAQ: TTPH
$ 6.47 +0.07 (1.09%)
Day High: 6.55
Day Low:  6.33
Volume:    272,911
4:00 PM ET
Oct 20, 2017

Delayed ~20 min., by eSignal.

Press Releases

Events & Presentations